Quantcast
Home > Quotes > ADXS
ADXS

Advaxis, Inc. Common Stock (ADXS) Quote & Summary Data

$0.4858
*  
0.0163
3.25%
Get ADXS Alerts
*Delayed - data as of Nov. 14, 2018 14:47 ET  -  Find a broker to begin trading ADXS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ADXS Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 0.4811 / $ 0.4858
1 Year Target
2
Today's High / Low
$ 0.52 / $ 0.4738
Share Volume
676,062
50 Day Avg. Daily Volume
969,975
Previous Close
$ 0.5021
52 Week High / Low
$ 3.58 / $ 0.4731
Market Cap
33,760,743
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.60
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.61

Intraday Chart

Shares Traded

Share Volume:
676,062
50 Day Avg. Daily Volume:
969,975

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.60

Trading Range

The current last sale of $0.4858 is 2.68% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.52 $ 3.58
 Low: $ 0.4738 $ 0.4731

Company Description (as filed with the SEC)

Advaxis, Inc. ("Advaxis" or the "Company") is a late-stage biotechnology Company focused on the discovery, development and commercialization of proprietary Lm Technology antigen delivery products based on a platform technology that utilizes live attenuated Listeria monocytogenes ("Lm") bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy by accessing and directing antigen presenting cells to stimulate anti-tumor T cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the Tumor Microenvironment ("TME") to enable the T cells to eliminate tumors. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape.  ... More ...  


Risk Grade

Where does ADXS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.5006
Open Date:
Nov. 14, 2018
Close Price:
$ 0.5021
Close Date:
Nov. 13, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x